Source: International Congress 2018 – Experimental research in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Abu-Hanna (London, United Kingdom), J. Taanman (London, United Kingdom), D. Abraham (London, United Kingdom), L. Clapp (London, United Kingdom). Impact of treprostinil on dynamin-related protein 1 (DRP1) and mitochondrial fragmentation in pulmonary arterial hypertension (PAH).. 3059

Member's Comments

No comment yet.

Related content which might interest you: Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Homeodomain-interracting protein kinase 2 (HIPK2) in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Arterial hypertension (AH) and endothelial function (EF) in patients with COPD Source: Annual Congress 2011 - COPD mechanisms Year: 2011 Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Role and regulation of Jumonji C domain-containing histone demethylases 1A and 2B in pulmonary hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 The inhibition of MRP4, a new target in pulmonary hypertension (PH), prevents and reverses hypoxia-induced pH in mice Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH) Source: Eur Respir J 2003; 22: Suppl. 45, 270s Year: 2003 Capillary lung volume (QC) and membrane conductance (DmCO) in patients with pulmonary hypertension: effects of tracleer Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD) Source: Eur Respir J 2005; 26: Suppl. 49, 564s Year: 2005 Endothelial cell mechanics are altered in pulmonary arterial hypertension (PAH) Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Effects of apoptosis signal- regulating kinase 1 (ASK1) inhibition in experimental pressure overload-induced right ventricular dysfunction Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Epoprostenol (EPT) for acute reactivity testing (AVT) in pulmonary artery hypertension (PAH) Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004